scispace - formally typeset
J

J. Mark Cooper

Researcher at University College London

Publications -  42
Citations -  10314

J. Mark Cooper is an academic researcher from University College London. The author has contributed to research in topics: Mitochondrial DNA & Substantia nigra. The author has an hindex of 31, co-authored 42 publications receiving 9349 citations. Previous affiliations of J. Mark Cooper include Royal Free Hospital.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy

Matthew E. Gegg, +5 more
- 15 Dec 2010 - 
TL;DR: Overexpression and RNAi studies indicated that PINK1 and parkin were required for mitophagy following CCCP-induced mitochondrial damage, and inhibition of this pathway may lead to the accumulation of defective mitochondria which may contribute to PD pathogenesis.
Journal ArticleDOI

Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains

Lydia Alvarez-Erviti, +6 more
- 13 Dec 2010 - 
TL;DR: It is demonstrated that decreased LAMP2A levels in dopaminergic cell lines reduced chaperone-mediated autophagy activity and increased the half-life of α-synuclein, suggesting that this pathway may be a suitable therapeutic target in PD.
Journal ArticleDOI

Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains

Matthew E. Gegg, +8 more
- 01 Sep 2012 - 
TL;DR: This work investigated the enzymatic activity of glucocerebrosidase (GCase) in PD brains carrying heterozygote GBA mutations (PD+GBA) and sporadic PD brains.
Journal ArticleDOI

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells

Alisdair McNeill, +10 more
- 25 Feb 2014 - 
TL;DR: Using Parkinson’s disease patient derived fibroblasts McNeill et al. show that Ambroxol treatment improved glucosylceramidase activity and reduced oxidative stress in these cells.